Dr. Bernard A Fox enters March with bi-coastal speaking engagements for cancer research
UbiVac CEO addresses medical conferences in Washington DC and San Francisco
Portland, Ore.— Dr. Bernard A. Fox, president and CEO of UbiVac, www.ubivac.com, a clinical stage immunotherapy biotechnology company, is recognized internationally as an authority on the fast-emerging medical specialty of immuno-oncology. In the last several months Dr. Fox has addressed cancer focused exchanges and workshops in Beijing, Naples, London, Chicago and San Diego.
This month his speaking agenda includes Washington DC for the Institute of Medicine (IOM), National Academy of Sciences National Cancer Policy Forum, and San Francisco for the Cambridge HealthTech Institute’s 23rd International Molecular Medicine TRI-CON.
Dr. Fox’s remarks at IOM focused on issues in “development and use of preclinical models for cancer immunotherapy.” His peers at the event included representatives of major pharmaceutical firms, the National Cancer Institute, university research and treatment centers, as well as health insurers, and the Food & Drug Administration. His participation was sponsored by the Earle A. Chiles Institute at Providence Cancer Center in Portland, Oregon, where he holds the Harder endowed chair.
The 2016 Molecular Medicine forum marked the first time that cancer immunotherapy was covered as a conference track in TRI-CON’s 22-year history. Participants included more than 3000 drug discovery and development professionals from more than 40 countries.
Dr. Fox presented details of the discovery process undertaken by UbiVac, along with its research and clinical partners, in developing and commercializing the company’s lead technology, DPV-001, a DC-targeted vaccine for patients with prostate, breast, head and neck, and non-small cell lung cancer.
UbiVac is a clinical stage Immuno-Oncology company engaged in development of immunotherapies to combat cancer. UbiVac’s DPV-001 is currently in a Phase II randomized multi-center adjuvant study for non-small cell cancer. UbiVac has ongoing preclinical and discovery programs using DRibble, nanoparticles and spread-defective Cytomegalovirus (sdCMV). Founded in Portland, Ore. in 2005 by Drs. Bernard A Fox and Hong Ming Hu, UbiVac is a spinout of the Robert W. Franz Center, Earle A Chiles Research Institute at Providence Portland Medical Center. In 2011 UbiVac, in cooperation with Oregon Health & Science University (OHSU), created UbiVac CMV to license sdCMV.